Cargando…

Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells

Antigen release resulting from the death of tumour cells induced by chemotherapies and targeted therapies can augment the antitumor responses induced by immune checkpoint blockade (ICB). However, tumours responding to ICB therapies often become resistant to them. Here, we show that the specific targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Gang, Wang, Ziyu, Zheng, Ningbo, Fang, Jing, Mao, Chengqiong, Li, Xiaoyin, Jin, Guangxu, Ming, Xin, Lu, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595849/ https://www.ncbi.nlm.nih.gov/pubmed/34725506 http://dx.doi.org/10.1038/s41551-021-00799-6

Ejemplares similares

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
por: Hiltbrunner, Stefanie, et al.
Publicado: (2023)

B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression
por: Hou, David, et al.
Publicado: (2023)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers
por: Tang, Yao, et al.
Publicado: (2022)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
por: Eissler, Nina, et al.
Publicado: (2016)

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
por: Arce Vargas, Frederick, et al.
Publicado: (2017)

Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells
por: Wu, Lin, et al.
Publicado: (2016)

Mathematical Modeling Reveals That the Administration of EGF Can Promote the Elimination of Lymph Node Metastases by PD-1/PD-L1 Blockade
por: Benchaib, Mohamed Amine, et al.
Publicado: (2019)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
por: Liu, Jian-Feng, et al.
Publicado: (2018)

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
por: Lee, Alexander H., et al.
Publicado: (2021)

Engineering ROS‐Responsive Bioscaffolds for Disrupting Myeloid Cell‐Driven Immunosuppressive Niche to Enhance PD‐L1 Blockade‐Based Postablative Immunotherapy
por: Li, Shaoyue, et al.
Publicado: (2022)

Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma
por: Bauer, Vera, et al.
Publicado: (2021)

Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
por: Repáraz, David, et al.
Publicado: (2022)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Induction in Pancreas Transplantation: T-cell Depletion Versus IL-2 Receptor Blockade
por: Aziz, Fahad, et al.
Publicado: (2022)

Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine
por: Cai, Mao-Hua, et al.
Publicado: (2018)

The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
por: Snanoudj, Renaud, et al.
Publicado: (2007)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2023)

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma
por: Yu, Guang-Tao, et al.
Publicado: (2015)

Depletion of PD-1-positive cells ameliorates autoimmune disease
por: Zhao, Peng, et al.
Publicado: (2019)

Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice
por: Ahn, Soon-Hyun, et al.
Publicado: (2019)

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients
por: Wei, Jia, et al.
Publicado: (2021)

Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
por: Aston, Wayne J., et al.
Publicado: (2019)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts
por: Veitch, Margaret, et al.
Publicado: (2023)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs
por: Gok Yavuz, Betul, et al.
Publicado: (2019)

Depletion of FAP(+) cells reduces immunosuppressive cells and improves metabolism and functions CD8(+)T cells within tumors
por: Zhang, Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r5o6393uc349ocvar1ioopk5dt